This review article evaluates the cardiovascular effects of the combination therapy of phentermine and topiramate (PHEN/TPM), marketed as Qsymia, for obesity treatment. Phentermine, a sympathomimetic amine, suppresses appetite, while topiramate, an anticonvulsant, promotes weight loss through mechanisms not fully understood. Clinical trials have demonstrated that PHEN/TPM leads to significant weight
